Exklusiver Live-Stream direkt von der World of Trading - 2 Tage mit einzigartigen Themen und Experten. Kostenlos teilnehmen + Videos erhalten. -w-
29.02.2008 19:00:00

Smith & Nephew Orthopaedic Reconstruction Global Management Team Announced

MEMPHIS, Tenn., Feb. 29 /PRNewswire-FirstCall/ -- Smith & Nephew, Inc.'s Orthopaedic Reconstruction Global Business Unit announced today the appointment of Todd Durniak as the senior vice president and general manager for its business in Asia and Australia. Durniak will focus on further developing the Unit's business in Asia and Australia, particularly in the areas of product development, surgeon education, marketing and supply.

Durniak's appointment rounds out the Unit's Global Management team, which also includes Andrew Holman, president for the Americas and Steve Couldwell, president for Orthopaedics Europe. The complete team reflects the Unit's geocentric business approach and commitment to improving the lives of patients worldwide through innovation and operational excellence. Couldwell, Holman and Durniak will report to Joseph DeVivo, president of Smith & Nephew Orthopaedic Reconstruction.

Joseph DeVivo said, "In order to maintain a balanced global growth strategy, we must lead locally, develop locally and educate locally. Andrew, Steve and Todd will focus on their local customer bases and align their respective organizations accordingly. We believe this global structure will provide our talented team with the flexibility to run the business efficiently and to make locally-orientated decisions that will enhance Smith & Nephew's offer to our clients and improve the lives of patients worldwide. I am excited about this new team, and look forward to seeing their leadership in action."

Todd Durniak

Durniak, 47, was previously the Vice President in charge of the business unit's Plus Orthopedics integration, which Smith & Nephew acquired in June 2007. Prior to leading the integration, Durniak was Vice President of Global Marketing for the Memphis-based Reconstructive division. He joined the company in June 2005 and has nearly 20 years of medical device experience including marketing leadership positions at Guidant and DePuy Orthopaedics. He holds a bachelor's degree in engineering from the University of Vermont and an MBA from Boston University.

Steve Couldwell

Couldwell, 47, was named president of Orthopaedics Europe in September 2005 and has been with Smith & Nephew for 18 years. Previously, Couldwell was the innovation and business development VP for the Advanced Wound Management global business unit. In this role, he was responsible for delivering high value innovation from the R&D pipeline; driving business development and facilitating future planning efforts. Prior to this role he was VP Global Sales and Marketing, also for Wound. Couldwell began his Smith & Nephew career in sales management and has also held leadership positions in human resources for Europe, distribution and commercial operations. He held sales and marketing posts with Warner Lambert (Pfizer) prior to joining Smith & Nephew. Couldwell holds a bachelor's degree in business studies from the University of Huddersfield, North Yorkshire.

Andrew Holman

Holman, 40, was appointed president of the Americas in September 2007, where he oversees sales, marketing, development, logistics and commercial operations in the U.S., North and South America. Holman joined Smith & Nephew in September 2005 as vice president, U.S. Reconstruction sales where under his leadership top line growth excelled. Holman has nearly 15 years of medical device experience, having previously held positions at Codman and Shurtleff, Inc., a subsidiary of Johnson & Johnson, Inc. and Boston Scientific. Holman holds a bachelor's degree in psychology and business administration from Rollins College.

Joseph DeVivo

DeVivo, 41, joined Smith & Nephew as president of the company's Orthopaedic Reconstruction business unit in June 2007. DeVivo has 18 years of marketing, development, sales, operations and executive leadership experience, having most recently served as President and Chief Executive Officer of RITA Medical Systems, Inc., a pioneer of radio frequency ablation technology, which was acquired by AngioDynamics in 2006. Previously, he served as President and Chief Operating Officer of medical robotics company Computer Motion, Inc., where he helped turn the company's performance around, ahead of its merger with Intuitive Surgery, Inc in 2003. From 1993 to 2002, DeVivo was at United States Surgical (USS), a division of Tyco Healthcare, where he held a wide variety of roles, including Vice President and General Manager of the USS/DG Sutures division, VP of global marketing, VP of global R&D and Director of Product Development. DeVivo holds a B.S. in Marketing and Management from the University of Richmond, Richmond, Va.

About Us

Smith & Nephew is a global medical technology business, specialising in Orthopaedic Reconstruction, Orthopaedic Trauma and Clinical Therapies, Endoscopy and Advanced Wound Management products. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2007 were nearly $3.4 billion.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding expected revenue growth and trading margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation, claims and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward- looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Analysen zu Smith & Nephew plcmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Smith & Nephew plc 11,67 1,48% Smith & Nephew plc

Indizes in diesem Artikel

FTSE 100 8 262,08 1,38%
FTSE Allshare 4 507,57 1,34%